On Friday 12 April, the European Commission approved biotech company Illumina’s plan to sell GRAIL (see EUROPE B13270A22).
The Commission prohibited Illumina’s acquisition of GRAIL on 6 September 2022, fearing that the merger would reduce choice in the emerging market for blood tests to detect cancers at an early stage. But Illumina and GRAIL had seriously breached European merger control rules by completing their deal while the Commission’s investigation was underway.
On...